7.62
0.21 (2.83%)
| Penutupan Terdahulu | 7.41 |
| Buka | 7.36 |
| Jumlah Dagangan | 8,181,727 |
| Purata Dagangan (3B) | 1,013,729 |
| Modal Pasaran | 377,533,664 |
| Harga / Jualan (P/S) | 4.20 |
| Harga / Buku (P/B) | 1.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -283.19% |
| Margin Operasi (TTM) | -256.55% |
| EPS Cair (TTM) | -5.01 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -16.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 48.37% |
| Nisbah Semasa (MRQ) | 3.05 |
| Aliran Tunai Operasi (OCF TTM) | -182.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -95.26 M |
| Pulangan Atas Aset (ROA TTM) | -26.03% |
| Pulangan Atas Ekuiti (ROE TTM) | -71.87% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | REGENXBIO Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.88 |
|
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 7.39% |
| % Dimiliki oleh Institusi | 92.34% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Integral Health Asset Management, Llc | 30 Sep 2024 | 1,275,000 |
| Aquilo Capital Management, Llc | 30 Sep 2024 | 930,708 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 52.00 (Chardan Capital, 582.42%) | Beli |
| Median | 35.00 (359.32%) | |
| Rendah | 18.00 (Raymond James, 136.22%) | Beli |
| Purata | 32.60 (327.82%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 9.41 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 11 Dec 2024 | 35.00 (359.32%) | Beli | 9.30 |
| HC Wainwright & Co. | 21 Nov 2024 | 36.00 (372.44%) | Beli | 9.18 |
| 07 Nov 2024 | 40.00 (424.93%) | Beli | 11.19 | |
| Chardan Capital | 20 Nov 2024 | 52.00 (582.41%) | Beli | 9.63 |
| 22 Oct 2024 | 52.00 (582.41%) | Beli | 9.59 | |
| Morgan Stanley | 15 Nov 2024 | 22.00 (188.71%) | Beli | 9.63 |
| Raymond James | 10 Oct 2024 | 18.00 (136.22%) | Beli | 9.29 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |